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OBJECTIVE — Ljunganvirus(LjV)hasbeenproposedasapotentialenvironmentalfactorfor
type 1 diabetes. The objective was to test for any association of LjV with type 1 diabetes.
RESEARCHDESIGNANDMETHODS — Anestedcase-controldesignwasusedtotest
for any association between the development of pre-diabetic autoimmunity and presence of LjV
in stool samples (n  3,803) in the Norwegian Environmental Triggers of Type 1 Diabetes
(MIDIA) study. The children followed were 27 infants who developed pre-diabetic autoimmu-
nity during or shortly after the sampling period, 54 matched control subjects, and 94 other
children.
RESULTS — No LjV RNA was detected.
CONCLUSIONS — TheresultsindicatethatLjVisrareinyoungchildren.LjVdoesnotseem
to be involved in the development of human type 1 diabetes.
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L
jungan virus (LjV), a rodent virus
described by Niklasson et al. (1),
has been associated with a variety
of conditions in rodents, including type
1 diabetes (2), myocarditis (3), and in-
trauterinedeath(4).Inhumans,LjVhas
been associated with intrauterine fetal
death (5), anencephaly (6), and sudden
infant death syndrome (7) and has been
suggested as a factor in type 1 diabetes
(2). LjV belongs to the viral family Pi-
cornaviridae, genus Parechovirus. The
genus also includes human parechovi-
rus (HPeV), which is common in in-
fancyandreplicatesmainlyinthegut.A
possible role of LjV in type 1 diabetes is
of particular interest because of the
strong association found in captive
bank voles (2,3,8).
The aim of the study was to investi-
gatethepresenceofLjVRNAinstoolsam-
ples to ﬁnd a possible association with
type 1 diabetes.
RESEARCH DESIGN AND
METHODS— A nested case-control
study was conducted, using 2,054 stool
samples from 81 children (27 case sub-
jects, 54 control subjects) all carrying the
DRB1*0401-DQA1*03-DQB1*0302/
DRB1*03-DQA1*05-DQB1*02 HLA ge-
notype, which gives the highest risk for
type 1 diabetes. Case subjects (10 boys,
17 girls) were deﬁned on development of
type 1 diabetes or of diabetes-associated
autoimmunity (being positive for two or
three autoantibodies: GAD, IA2, or IAA).
Control children (31 boys, 23 girls) were
matched for birth date and geographical
residence.Thisdatasetwasmergedwitha
previously published dataset investigat-
ing parechovirus infections (9) in 1,941
stool samples from 102 children (51 with
the high-risk genotype and 51 without).
In total, there were 3,803 unique samples
from 175 children (86 boys, 89 girls),
since some children participated in both
studies. The children represented 16 of
19 municipalities in Norway.
Monthly stool samples, from 3 to 35
months of age, were collected by parents
as previously described (10); the age dis-
tribution is shown in Fig. 1. The samples
were collected between 2001 and 2008;
because most children were followed for
atleast1year,therewasanequalseasonal
distribution of samples. The median fol-
low-up was 30 months for the stool sam-
ples (range 9–37 months), with median
end point (autoimmunity) of the cases at
20.5 months (range 6–43). The presence
of LjV was examined by extraction of
RNA/DNA, reverse transcription (RT),
and real-time PCR as described by Tapia
et al. (9), with minor modiﬁcations of the
protocol due to introduction of a 96-well
formatandtheuseoftheantisenseprimer
describedbyDonosoMantkeetal.(11)as
the RT primer. Two positive control sub-
jects were included from extraction to
PCR run (140 and 70 copies of a tran-
script from a plasmid containing a cDNA
cloneofLjVprototypestrain87-012,pro-
vided by Professor Lindberg, University
of Kalmar, Sweden). A fragment of West
Nile Virus RNA was spiked into the sam-
ples as an exogenous internal control
(10). The study was approved by the Re-
gional Committee for Medical Research
Ethics and the Norwegian Data
Inspectorate.
RESULTS— No LjV RNA was de-
tected in any of the stool samples investi-
gated, neither from the 27 children who
had developed autoimmunity, nor from
the 54 matched control subjects and the
94 healthy children previously tested.
The positive LjV control was consistently
detected, and the West Nile Virus Ar-
mored RNA used as an exogenous in-
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follow-up time, the number of tested sam-
ples,andthatbothpre-diabeticandhealthy
children were tested, these results indicate
that LjV is very rare in the stool of Norwe-
gian infants. The typical stool quantities of
human enterovirus and HPeV in samples
from the Norwegian Environmental Trig-
gers of Type 1 Diabetes (MIDIA) cohort
study were two to ﬁve orders of magnitude
higher than the detection limit for LjV
(9,12);presumablyanyappreciablereplica-
tion of LjV in the gut would be detected.
The detection of the exogenously added
West Nile virus RNA safeguards against the
presence of inhibitors and RNA degrada-
tion. The primers used consistently de-
tected the positive LjV RNA controls
included in each run and are expected to
detect all strains of LjV. No change in sen-
sitivity was detected with the introduction
of a 96-well extraction method. The use of
the antisense primer in the RT reaction
could be presumed to increase the sensitiv-
ity at the cost of the formation of more spu-
rious products, but was chosen to ensure
that any possible positive sample would be
detected. The lack of evidence for the pres-
ence of LjV suggests that this virus rarely
infects the gut of Norwegian infants, and it
seems unlikely that the virus is the cause of
the autoimmunity observed in the present
study.
Picornavirusesmayalsoreplicateout-
side the intestinal tract and may cause
viremia or respiratory infections. Al-
though one would expect a gastrointesti-
nal route of infection in the case of LjV,
the virus might reach the pancreas even
after limited replication in the gut. Al-
though data supporting LjV infections in
humans have been published, there is so
far no conclusive evidence. The arguably
strongest evidence stems from prenatal
studies (5,6). In these studies, the pres-
enceofvirushasbeensuggestedpartlyby
serology and partly by PCR; but, as
pointed out by Bergstrom et al. (13), dif-
ferent methods do not seem to give con-
gruent results. Moreover, the PCR
positivityobservedintheearlierstudiesis
not reported to have been conﬁrmed by
sequencing. Although the evidence sug-
gests possible human LjV infections, the
dataalsoindicatethatitisarareeventand
primarily during the prenatal period.
The likelihood of infection may also
be geographically speciﬁc and dependent
on the cycles of its natural reservoir,
whichpresumablyarebankvolesinScan-
dinavia. Although common in Norway,
their prevalence in the communities from
which infants in the present study was
recruited is not known. Thus, the possi-
bility that the infants investigated were
never exposed cannot be ruled out.
In conclusion, although the present
data do not rule out the possibility that
LjV can cause type 1 diabetes, they do
suggest that this virus is not a common
risk factor in the etiology of the disease in
Norway.
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